Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223697 · ClinicalTrials.gov registry record · Phase 2
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 7
- Study locations
NCT07223697 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 120 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT07223697, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Conditions Studied
Interventions
- DRUG Afimkibart
Study Locations (7)
Other
- Centrum Nowoczesnych Terapii "Dobry Lekarz" - Krakow
- Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie - Rzeszów
- Klinika Ambroziak Dermatologia - Warsaw
Michigan
- Revival Research Institute, LLC - Troy
Pennsylvania
- Best Skin Research LLC - Camp Hill
Ontario
- DermEdge - Mississauga
Silesian Voivodeship
- Centrum Medyczne Pratia Katowice I - Katowice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2033-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223697
The ClinicalTrials.gov registry entry for NCT07223697 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (80% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Afimkibart is the first listed.
NCT07223697 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07223697 about?
NCT07223697 is a clinical study titled "A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis". This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
What is the current status of trial NCT07223697?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-01-08. Estimated completion is 2033-02-11.
What conditions does trial NCT07223697 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07223697?
The interventions under investigation include: Afimkibart (DRUG).
Who is sponsoring clinical trial NCT07223697?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223697 being conducted?
This trial has 7 study locations across Michigan, Pennsylvania, Ontario, Silesian Voivodeship. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.